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Abstract
TGF-β potently induces apoptosis in Burkitt’s Lymphoma (BL) cell lines and in explanted
primary human B lymphocytes. The physiological relevance and mechanism of TGF-β-mediated
apoptosis induction in these cells remains to be determined. Here we demonstrate the requirement
for TGF-β-mediated regulation of BIK and BCL-XL to activate an intrinsic apoptotic pathway in
centroblastic BL cells. TGF-β directly induced transcription of BIK and a consensus Smad
binding element identified in the BIK promoter recruits TGF-β-activated Smad transcription factor
complexes in vivo. TGF-β also transcriptionally repressed expression of the apoptosis inhibitor
BCL-XL. Inhibition of BCL-XL sensitised BL cells to TGF-β-induced apoptosis while
overexpression of BCL-XL or suppression of BIK by shRNA, diminished TGF-β-induced
apoptosis. BIK and BCL-XL were also identified as TGF-β target genes in purified normal human
centroblast B cells and immunohistochemical analyses of tonsil tissue revealed widespread TGF-β
receptor-regulated Smad activation and a focal pattern of BIK expression. Furthermore, using a
selective inhibitor of the TGF-β receptor we provide evidence that autocrine TGF-β signaling
through ALK5 contributes to the default apoptotic program in normal human centroblasts
undergoing spontaneous apoptosis. Our data suggests that TGF-β may act as a physiological
mediator of human germinal centre homeostasis via regulation of BIK and BCL-XL.
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Introduction
Transforming growth factor-beta (TGF-β) is the prototypical member of a superfamily of
pleiotropic cytokines which regulate a multitude of biological processes including tissue
homeostasis, angiogenesis, migration and differentiation. TGF-β signals via activation of a
heterooligomeric receptor complex consisting of the type II receptor, TGFβ-RII and the type
I receptor ALK5. These receptors activate a diverse range of intracellular signal transduction
pathways including the canonical Smad pathway. The receptor-associated Smads 2 and 3
(R-Smads), are directly phosphorylated on their carboxy termini by the serine/threonine
kinase domain of ALK5. Following phosphorylation the R-Smads heterooligomerise with
the co-Smad, Smad4, and accumulate in the nucleus where in conjunction with a number of
cofactors they regulate target gene expression.1
TGF-β acts as a potent immunosuppressor by regulating the proliferation and survival of
many cells of the immune system. Part of the homeostatic function of TGF-β is the cell-type
specific induction of apoptosis which occurs in several cell types including B cells2. Gene
ablation studies in mice have indicated that TGF-β signaling affects B cells at all stages of
development and is critical for secreted IgA responses3. The observation that many
lymphomas (including those derived from germinal centre B cells undergoing
differentiation) have defective TGF-β signaling pathways4,5 suggests that disruption of
TGF-β apoptotic signaling in human B cells may contribute to lymphomagenesis.
Germinal centres (GCs) are the main sites for generating high-affinity antibody responses
through repeated rounds of selection by apoptotic elimination of unwanted B cells.
Activated B cells entering GCs undergo a process where immunoglobulin genes are altered
by somatic hypermutation. Over time, cells carrying mutated receptors with the highest
affinity for foreign antigen out-compete others for limiting amounts of antigen and survival
signals provided by T-cell help, so ensuring their continued survival and differentiation.6 At
present, cell death at this site is generally thought to occur by FAS-dependent apoptosis
(required for deletion of cells carrying low affinity mutated immunoglobulins7). In addition,
B cell receptor (BCR) ligation in the absence of co-stimulatory receptor-ligand interactions
is important for deletion of autoreactive B cells. In this context, FAS-mediated apoptosis is
inhibited by cFLIPL induced by survival signals from CD40 and B cell receptor (BCR)
ligation. In the absence of these signals (for example during in vitro culture) cFLIP is
rapidly degraded leading to spontaneous apoptosis8, a process known as ‘death by neglect’.
GC B cells are therefore primed to die and require continued environmental cues for
survival.
Signaling via CD40 and the BCR may help to render B cells ‘Fas-resistant’ by induction of
the pro-survival BCL-2 homologue, BCL-XL, although there are conflicting reports of its
involvement in Fas-mediated cell death9. It is likely however, that BCL-XL or BCL-2
expression induced by survival signals is required to antagonise a mitochondrial ‘intrinsic’
apoptosis pathway activated by antigen-BCR interaction. BCR-mediated cell death
correlates with induction of BIM10 which is a member of the pro-apoptotic BCL-2 family of
proteins that also includes BIK, NOXA, BAD, BID, BMF and PUMA. These proteins
antagonise the function of BCL-2 and its pro-survival homologues (BCL-XL, BCL-w,
MCL-1, and A111) resulting in activation of BAX and BAK. Once activated, BAX and
BAK permeabilise the mitochondrial outer membrane12 to release apoptogenic factors
including cytochrome c which complexes with APAF1 and pro-caspase 9 to form the
apoptosome. Knockout mouse studies have implicated several pro-apoptotic components of
this pathway in B cell homeostasis.10
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Previous findings suggest that TGF-β-mediated apoptosis may also be involved in normal
human GC B cell homeostasis. For example, we and others have shown that some Burkitt’s
Lymphoma (BL) cell lines (which derive from B cells differentiating within GCs) are highly
sensitive to TGF-β-induced apoptosis.5,13,14 Exogenous TGF-β also enhances apoptosis of
primary explanted human and murine B lymphocytes.3 However, the physiological role of
TGF-β signaling in GC reactions, the cell types within this compartment which die in
response to TGF-β, and the effector mechanisms TGF-β employs to induce apoptosis remain
to be elucidated.
Here we demonstrate that TGF-β contributes to ‘death by neglect’ by regulating an intrinsic
apoptotic pathway in human centroblastic B cells. TGF-β impacts on apoptosis regulators
upstream of BAX and BAK, by inducing the pro-apoptotic BH3-only protein BIK and
downregulating BCL-XL. These changes occurred both in BL cell lines and in their normal
GC counterparts (centroblasts). Blocking the TGF-β-induced intrinsic pathway in primary
human centroblasts provided cells with a survival advantage during spontaneous apoptosis.
Our findings identify autocrine TGF-β signaling as a physiological regulator of a default
mitochondrial apoptotic pathway in human B cells, and identify a novel function for BIK in
B cell homeostasis.
Results
Engagement of the intrinsic mitochondrial apoptosis pathway by TGF-β
To determine how TGF-β regulates apoptosis in centroblastic Burkitt’s Lymphoma cells, we
studied the response of a panel of BL cell lines to exogenous TGF-β. Ramos, BL2 and BL40
cells died following TGF-β addition shown by cleavage of the caspase substrate PARP,
however, CA46 cells showed no PARP cleavage despite having an intact TGF-β signaling
pathway (measured by phosphorylation of Smad2) (Figure 1a).
We next analysed mitochondrial membrane integrity in apoptotic BL cells to determine
whether the intrinsic pathway was activated by TGF-β. The gradual loss of the
mitochondrial stain TMRE during 48 hours treatment of BL cells is consistent with
involvement of the intrinsic mitochondrial pathway in TGF-β-induced apoptosis of BL cells
(Figure 1b).
TGF-β regulates multiple BCL-2 family members
Induction of the intrinsic apoptosis pathway requires activation of BAX/BAK which in turn
is controlled by other members of the BCL-2 family. We therefore screened for
transcriptional changes in BCL-2 family members during TGF-β-induced apoptosis.
Multiprobe RNase protection assays (RPAs) demonstrated that TGF-β addition caused a
rapid increase in transcripts of the pro-apoptotic BH3-only protein BIK in BL2 cells (Figure
2a) and in Ramos and CA46 BL cells (Supplementary Figure 1a). Elevated BIK expression
in CA46 cells was initially surprising, since CA46 cells do not apoptose in response to TGF-
β (Figure 1a and ref.5), however, further investigation confirmed previous reports15 that
CA46 cells lack the mitochondrial membrane protein BAX (Supplementary Figure 1b)
required for intrinsic apoptosis.
As well as inducing BIK, TGF-β treatment also rapidly decreased RNA expression of BCL-
XL in BL2 (Figure 2a), Ramos and CA46 cells (Supplementary Figure 1c). These effects
were mirrored at the level of protein expression (Figures 2b and 2c), although the kinetics of
BIK induction were more rapid than loss of BCL-XL expression. No induction of BIM (a
known TGF-β target gene16,17) was observed (Figure 2b and Supplementary Figure 2a,
2b). BL2 cells lacked BIM expression altogether, but died efficiently upon exposure to TGF-
β, indicating that BIM is unlikely to mediate the apoptotic response in the BL cell lines
Spender et al. Page 3
Cell Death Differ. Author manuscript; available in PMC 2010 April 20.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
studied. In addition, we observed no change in MCL-1 levels or in BID expression or
cleavage to the pro-apoptotic 15kDa form, tBid (Supplementary Figure 2b). TGF-β-
mediated apoptosis in BL cells therefore correlated primarily with effects on BIK and BCL-
XL.
To address whether these events are critical for apoptosis, we obtained BL cells stably over-
expressing BCL-XL18. Elevated levels of BCL-XL expression in the stably transfected cells
(maintained throughout exposure to TGF-β) reduced the proportion of cells containing
active caspase-3 (Figure 3a) and reduced cleavage of PARP induced by TGF-β (Figure 3b).
Increased BCL-XL expression therefore largely protected BL cells from TGF-β-mediated
apoptosis thus confirming the involvement of mitochondria in the response. To investigate
further whether BCL-XL is critical for BL cell survival, we used an inhibitor to block the
function of endogenous BCL-XL. BH3i-2′ inhibits BCL-2 and BCL-XL by binding to their
BH3 binding pocket.19 Since BL2, Ramos and BL40 cell lines express BCL-XL but lack
BCL-2 protein expression (Figure 3c) we used BH3i-2′ as a selective inhibitor of BCL-XL
in BL cells. All three cell lines apoptosed upon treatment with 30μM BH3i-2′. BL2 cells,
which express a lower amount of BCL-XL than either Ramos or BL40, were sensitive to
5μM of the inhibitor (Figure 3d). Significantly, we were able to sensitise BL cells to TGF-β-
induced apoptosis using low dose BCL-XL inhibitor (5μM) (Figure 3e). Apoptosis induction
was greater following combined treatment than was observed with either TGF-β or the
BCL-XL inhibitor alone. The synergistic apoptotic response demonstrates that BCL-XL
regulation is an important factor in TGF-β-induced apoptosis in BL cells.
To test whether BIK induction is also required for optimal induction of apoptosis, we used a
stable shRNA knockdown approach. Non-silencing control and BIK shRNA retroviral
vectors were generated to establish stable Ramos cell lines. qRT-PCR analysis revealed BIK
shRNAs reduced expression to below basal levels in comparison with the non-silencing
vector (Figure 3f). Importantly, BIK knockdown resulted in a substantial reduction in TGF-
β-mediated apoptosis (Figure 3g) without affecting TGF-β signaling (data not shown).
Taken together, these findings reveal that the levels of BIK and BCL-XL play a critical role
in regulating TGF-β-dependent apoptosis in centroblastic BL cells.
BIK and BCL-XL are direct and indirect TGF-β target genes
We next investigated the mechanism of TGF-β regulation of BCL-2 family members firstly
by testing whether BCL-XL and BIK are immediate early targets of TGF-β signaling. RPA
analysis showed that repression of BCL-XL required protein synthesis since pre-treatment of
cells with cycloheximide and anisomycin prevented the decrease in BCL-XL RNA levels
(Figure 4a). Induction of BIK however, still occurred under these conditions but was
completely blocked by inhibiting transcription with actinomycin D (Figure 4a and 4b)
demonstrating that BIK is a direct, transcriptional target of TGF-β signaling.
The control of BCL-XL transcription is complex, involving multiple promoters whose
activity appears to be cell type and context dependent.20 Since the histone deacetylases
(HDACs)- 4 and 5 can be involved in repression of promoters by TGF-β21, we treated BL
cells with an inhibitor of class I and class II HDACs, Trichostatin A (TSA), to gain insight
into the possible mechanism of repression of BCL-XL.. As expected, TGF-β treatment for 8
hours decreased the amount of BCL-XL RNA expressed in both BL2 and BL40 cells. TSA
pre-treatment of BL cells to inhibit HDAC function, completely blocked the ability of TGF-
β to repress BCL-XL transcription (Figure 4c) without affecting TGF-β signaling (Figure
4d). In fact, loss of HDAC function switched the response to TGF-β from one of repression
to one of activation (in agreement with previous studies of the osteocalcin promoter).21
TGF-β regulation of BCL-XL transcription may therefore involve chromatin remodelling
through the recruitment of repressor complexes containing class I or II HDACs.
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Our studies indicate that BIK is an immediate early target of TGF-β signaling in BL cells,
and therefore is likely to be activated by Smad complexes. Smad binding regions (SBRs)
often contain 2 copies of the Smad binding element (SBE) sequence 5′ GTCT 3′ or its
reverse complement 5′AGAC 3′22. We identified two potential SBRs approximately 1.1Kb
upstream of the BIK transcription start site (Figure 4e). Chromatin immunoprecipitation
(ChIP) analysis using primers spanning this region demonstrated the TGF-β-dependent
recruitment of Smads 3 and 4 to the endogenous BIK promoter in BL cells in vivo (Figure
4f). Radiolabelled dsDNA probes of SBR1 and SBR2 were prepared (wild type and mutant
SBR2 sequences are shown in Figure 4g) and used in electrophoretic mobility-shift assays
(EMSA) to determine which SBR in the region assayed by ChIP could bind Smad
complexes in vitro. SBR2 bound a TGF-β inducible complex which could be supershifted
with Smad3 and Smad4 antibodies (Figure 4h). SBR1 and a mutated form of SBR2 which
abrogates the consensus SBEs, were unable to bind Smad3/4 complexes (Figure 4h). These
data suggest that TGF-β activates BIK by direct binding of transcriptionally active Smad3/4
complexes to the SBR2 sequence within the promoter.
Autocrine TGF-β signaling in primary human centroblasts
Burkitt’s Lymphomas originate within GCs and phenotypically resemble centroblasts.
Exogenously added TGF-β enhances apoptosis of GC B cells in vitro23 but the mechanism
of induction and what contribution TGF-β makes to normal GC development is not fully
understood. Having determined how TGF-β induces apoptosis in BL cell lines, we studied
whether these responses occur in primary human tonsil cells. In addition to studying the
effects of exogenously added TGF-β, we used SB-431542, a selective inhibitor of ALK524,
to block endogenous TGF-β signaling. Total mononuclear cells (TMCs), purified CD77+ve
centroblasts (isolated by positive selection), and TMCs depleted of CD77 positive cells
responded to exogenous TGF-β as shown by increased Smad2 and Smad3 phosphorylation
(Supplementary Figure 3a). Interestingly, active Smad2 was also detected in untreated cells
cultured for 1 hour in serum free medium. This endogenous signaling was completely
ablated by treatment with SB-431542 (Supplementary Figure 3a) which suggests that, in the
absence of external sources of cytokine, autocrine TGF-β signaling via the ALK5 receptor
occurs in GC B cells and isolated centroblasts. Consistent with this, we found that
centroblasts express TGF-β1 mRNA (Supplementary Figure 3b).
ALK5 inhibition enhances centroblast survival
Since centroblasts exhibit endogenous TGF-β signaling and respond to increased doses of
TGF-β, we examined the biological consequences of signaling. Firstly we analysed by flow
cytometry (FCM) the survival of centroblasts (CD38/CD77 double positive cells) in
populations of TMCs cultured with either TGF-β or SB-431542. During in vitro culture the
percentage of double positive cells decreased. This process was enhanced by addition of
TGF-β and partially suppressed by treatment with SB-431542 relative to controls (Figure
5a). Similar results were obtained with CD77 staining alone (Figure 5b), enabling the use of
CD77 positive selection purification techniques to examine further the role of TGF-β
signaling in these cells.
Culture of purified centroblasts resulted in spontaneous apoptosis shown by PARP cleavage
(Figure 5c, lane 2). Treatment with the mitogen, PMA, partially rescued centroblasts from
spontaneous apoptosis but was unable to overcome cell death induced by addition of TGF-β
(Supplementary Figures 4a and 4b). Interestingly, when centroblasts were cultured with
SB-431542 we were able to consistently prolong cell survival shown by a reduced PARP
cleavage (Figure 5c). In addition, we detected fewer centroblasts containing active caspase-3
following isolation and culture with the ALK5 inhibitor (Figure 5d). No PARP cleavage was
evident in any CD77 depleted TMCs (Supplementary Figure 4a) despite apoptosis taking
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place in whole TMC cultures (data not shown). Thus we conclude that CD77+ve cells are
the only cell type present in TMCs that apoptose in response to TGF-β and that blocking
endogenous signaling with a selective inhibitor of ALK5 provides these cells with a survival
advantage following withdrawal of environmental cues.
TGF-β regulates BIK and BCL-XL in primary human centroblasts
To assess whether apoptosis induction is mechanistically similar in both BL cell lines and
their normal GC counterparts we analysed whether TGF-β signaling can be detected in
intact germinal centres, and whether BIK and BCL-XL are also TGF-β target genes in
primary human centroblasts. Formalin fixed, paraffin embedded tonsil tissues were stained
for phosphorylated Smad2 and Ki67, a marker of proliferation (Figure 6a). Ki67 highlighted
dark and light zones of the GC. Phosphorylated Smad2 was readily detected within both
zones as well as in the surrounding mantle zone. A more restricted expression pattern of
BIK was detected within the dark and light zones of GCs.
RPA analysis demonstrated that purified CD77+ve cells express BCL-XL, and high levels of
BIK RNA (Supplementary Figure 5). BCL-2 was poorly expressed confirming previous
observations.25 Western blotting of lysates from tonsil mononuclear cells (TMC), purified
CD77 positive cells and TMCs depleted of centroblasts revealed that while BIK protein
could only be detected very weakly in TMCs, purified CD77 positive cells were strongly
positive for BIK, demonstrating that BIK expression is restricted to centroblasts (Figure 6b).
qRT-PCR analysis carried out on purified centroblasts treated with the pan-caspase inhibitor
ZVAD to inhibit apoptosis showed that BIK and BCL-XL RNA levels were significantly
increased and reduced respectively by TGF-β addition while the levels of BIM were
unchanged (Figure 6c). Taken together, the findings reveal that TGF-β signaling is
widespread during germinal centre reactions and that the effectors of apoptotic responses
induced by TGF-β in BL cell lines and primary centroblasts are identical.
Discussion
This study reveals that TGF-β mediates apoptosis in germinal centre derived B cells via a
mitochondrial intrinsic pathway (Figure 1b). The mechanism of apoptosis induction
involved transcriptional regulation of the BCL-2 family members, BIK and BCL-XL
(Figures 2 and 4). In addition, we provide the first evidence of a causal relationship between
BIK and TGF-β-induced apoptosis (Figure 3g) and show that BCL-XL is important for BL
cell survival and the outcome of their response to TGF-β signaling. Overall our data
indicates that the relative levels of BIK and BCL-XL dictates the apoptotic response of
centroblastic cells to TGF-β. We might therefore also predict that cross-talk between the
TGF-β and BCR receptor signaling pathways is likely, since BIK (as well as BIM) may be
regulated by BCR ligation.26
Upon induction, BH3-only proteins like BIK induce apoptosis by binding directly to pro-
survival BCL-2 family members which constrain BAX and BAK activation. BIK has been
described as promoting cell death by sequestering BCL-2 and BCL-XL27 and antagonising
MCL-1 and BCL-XL during apoptosis caused by protein synthesis inhibition.28 Since
centroblastic cells express very little BCL-2 (Supplementary Figure 5 and ref 25) induction
of BIK in this cell type is more likely to antagonise the function of BCL-XL and/or MCL-1.
Indeed, maintaining BCL-XL protein levels in BL cell lines partially overcame the apoptotic
effects of TGF-β (Figures 3a and 3b), while inhibiting BCL-XL function sensitised BL cells
to the effects of TGF-β (Figure 3e). Given the important role of BCL-XL in the TGF-β-
mediated apoptotic response, it is possible that the defect in GC apoptosis seen in Bcl-XL
transgenic mice, which results in “relaxed” negative selection and impaired affinity
maturation29, could be a consequence of a defective default TGF-β apoptosis program.
Spender et al. Page 6
Cell Death Differ. Author manuscript; available in PMC 2010 April 20.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
BIK is transcriptionally regulated by p5330 and E2F-131,32, and we now identify BIK as a
novel TGF-β target gene in human B cells via Smad recruitment to the promoter. Our
conclusion that BIK is involved in B cell homeostasis is supported by the observations that
mice with a heritable defect resulting in elevated levels of BIK RNA, have higher levels of
apoptosis in splenic B cells, and normal B cell development can be restored by BCL-XL
overexpression33. On the other hand, Bik-/- mice appear quite normal and their B cells are
still sensitive to spontaneous apoptosis.34 To reconcile these observations, it is possible that
murine and human B cells respond differently in some respects to TGF-β signaling.
Significantly, the SBR recruiting Smads to the endogenous human BIK promoter (shown in
Figure 4e and 4f) is not conserved in the mouse or rat (data not shown), indicating that BIK
is unlikely to be involved in TGF-β-regulated germinal centre homeostasis in mice.
Using a selective inhibitor of TGF-β receptor function, we also show that TGF-β signaling
through ALK5 is an important physiological modulator of apoptosis of human centroblasts
in the absence of survival stimuli (Figure 5). It is possible that exogenous sources of TGF-β
may contribute to the regulation of centroblasts in vivo, nevertheless, purified centroblasts
exhibited phosphorylation of Smads in the absence of serum and express TGF-β1 RNA
(Supplementary Figure 3b), suggesting that treatment of the cells with SB-431542 inhibits a
functional autocrine TGF-β signaling pathway.
Thus far, we have not yet fully elucidated the mechanism of BCL-XL repression.
Transcriptional regulation of BCL-XL is complex, involving numerous different
transcription factors and three distinct promoters regulating initiation at the 5′end of two
non-coding exons, IA and IB, and at the beginning of exon II.20 One possible mechanism of
BCL-XL regulation by TGF-β is through increased expression of the TGF-β-induced early
genes 1 and 2 (TIEG1 and TIEG2) which regulate BCL-XL levels in oligodendroglial
precursor cells.35 TIEG-1 was undetectable in BL cells by Western blotting, and while
TIEG2 was expressed its levels were unaltered by TGF-β (LS, unpublished observations). It
therefore seems unlikely that induction of either TIEG1 or 2 is involved in BCL-XL
regulation in BL cells. However, our data suggests that (as in the case of TGF-β-mediated
repression of osteocalcin) chromatin remodelling in the form of recruitment of HDAC-
containing repressor complexes may be involved. Studies are currently underway to
characterise the mechanism of repression further.
A Model of Centroblast death
Overall our data provides evidence for a revised model of centroblast apoptosis (Figure 7) to
include the novel involvement of TGF-β in regulating an intrinsic apoptosis pathway. We
propose that autocrine TGF-β signaling through ALK5 contributes to the default apoptotic
state apparent in centroblasts lacking survival stimuli. Parallel Fas (extrinsic) and TGF-β
(intrinsic) pathways converge to regulate death by neglect, via caspase-8 and caspase-9
respectively. In line with this, chemical inhibition of caspase-9 activity in explanted GC B
cells enhances their survival.36 Our data implies that survival signals provided during
affinity maturation must overcome both pathways.
Our data also suggests that defective TGF-β signaling would provide GC B cells with a
survival advantage during selection. Indeed many lymphomas of B cell origin have aberrant
TGF-β signaling or defects in downstream components of the signaling pathway4 while
mutations in BIK have been reported in B cell lymphomas of GC origin.37 We hypothesise
therefore that disruption of the TGF-β regulated apoptotic program in human B cells may
contribute to lymphomagenesis and/or autoimmune pathology.
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Materials and Methods
Cell Lines and reagents
BL cell lines were maintained in RPMI-1640 (Gibco-BRL) supplemented with 5-10% (v/v)
heat-inactivated FCS, 2mM/ml glutamine and antibiotics. Cells were treated as required with
1ng/ml TGF-β1 (Peprotech), 50μM zVAD-fmk (Calbiochem) and 10μM SB-431542
(Tocris). Protein synthesis inhibition was carried out by pre-incubation for 2 hours with
50μg/ml cycloheximide and 100μM anisomycin (Sigma). Inhibition of transcription was
carried out by pre-treatment of cells for 1 hour with 2.5μg/ml actinomycin D (Sigma). The
inhibitor of BCL-XL function (BH3i-2′) was purchased from Calbiochem and reconstituted
in DMSO at a concentration of 15mM. For inhibition of HDAC function cells were
pretreated for 15 minutes with 330nM Trichostatin A (Sigma).
Isolation of centroblasts
Ethical permission was obtained for collection and use of normal tonsil tissue (confirmed on
histology) from the Southern General Hospital Ethics Committee (Reference EC/04/S/06)
and registered with the Research and Design Office (reference R040016) following routine
tonsillectomy. Tonsil mononuclear cells (TMC) were isolated by Ficoll density gradient.
CD77+ve cells were purified using rat anti-human CD77 (Immunotech) followed by mouse
anti-rat IgM (BD biosciences) and rat anti-mouse IgG1 microbeads (Miltenyi Biotech). Cells
were purified using an AutoMacs (Miltenyi Biotech) and were cultured at 37°C in RPMI
plus 15% FCS at 1×107/ml.
Immunoblotting and antibodies
RIPA lysates were analysed by SDS-PAGE. Antibodies used in Western blotting were
mouse monoclonals against PARP (BD Biosciences), BIK (FL-160, Santa Cruz), Smad 2/3
(BD Biosciences), and actin (Sigma) and rabbit polyclonal antibodies against phospho-Smad
2 (ser465/476), phospho-Smad 3 (ser 433/435), BID and BCL-XL (Cell Signaling), MCL-1
(Santa Cruz) and BIM (Chemicon). Secondary HRP-conjugated antibodies were obtained
from Dako. Bound immunocomplexes were detected by enhanced chemiluminescence
(ECL; Amersham). Prestained protein marker sizes are shown on each gel.
Analysis of cell surface markers by flow cytometry
1×106 cells in PBS/0.5% BSA were labelled on ice for 1 hour with the appropriate
concentration of antibody before being washed and analysed by flow cytometry (BD
FACScan or FacsCalibur). Antibodies used were PE-conjugated anti-CD38 and FITC-
conjugated anti-CD77 (BD Biosciences). At least 104 events were acquired and analysed
using CellQuest software. Analysis gates were set to include 1% of cells of an unstained or
isotype matched control stained population.
Analysis of apoptosis by flow cytometry
Cells were fixed, labelled with propidium iodide (PI) and analysed by flow cytometry for
sub-2N DNA content, or analysed by measuring intracellular caspase-3 activity using
fluorogenic peptide substrates of caspase-3 (PhiPhiLux, G1D2, Calbiochem) as
recommended by the manufacturer. To monitor mitochondrial membrane potential, cells
were incubated for 20mins in medium containing 40nM of the mitochondrial stain TMRE
(Molecular Probes). Treatment with CCCP induced complete mitochondrial membrane
depolarisation as a positive control.
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RNase protection assay (RPA)
Total cellular RNA was extracted using Trizol. RPAs were carried out as described
previously38 using the hApo2b multiprobe template set (BD Biosciences Pharmingen).
Retroviral infection of BL cell lines
shRNA-mirs targeting BIK were generated using oligonucleotides described in
supplementary text cloned into MSCV/LTRmiR30-PIGΔRI (LMP) [a kind gift of Ross
Dickins and Scott Lowe]39 Amphotropic retroviruses were generated as described in
supplementary materials and methods. BL cells, seeded at 5000 cells/well in 96-well plates,
were infected with viral supernatants by centrifugation at 37°C, 4000×g for 1.5 hours. Cells
were incubated overnight prior to addition of growth medium containing 0.6μg/ml
puromycin. Stable cell pools were analysed directly after outgrowth in selection medium.
qRT-PCR
Total cell RNA was isolated using Trizol as recommended by the manufacturer. cDNA and
qRT-PCR reactions were prepared using SYBR green 2-step qRT-PCR kits (Finnzymes) and
specific primers for each gene (Qiagen). Amplified products were analysed by Chromo4
continuous fluorescence detector and Opticon Monitor3 software. The relative amount of
RNA for each gene expressed after normalisation to the amount of 18s rRNA in each
sample.
ChIP assay
2×107 CA46 cells were treated with 1ng/ml TGF-β for 1 hour and fixed in 1% formaldehyde
for 15 minutes. Samples were prepared as described in supplementary text prior to analysis
by PCR.
Immunohistochemistry
Sections (2μm) of formalin fixed- paraffin embedded human tonsil tissue were stained with
antibodies raised against Ki67, BIK or phospho-Smad 2 as described in supplementary
materials and methods.
EMSA
Band shifts were performed as described40 using the ds oligos described in supplementary
materials and methods. A total of 5μg of nuclear extract derived from the appropriate cell
type and condition was incubated with radiolabelled oligonucleotide probes. For supershifts,
anti-Smad3 (Zymed) and anti-Smad4 (Santa Cruz) were also included.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
BL Burkitt’s Lymphoma
GC germinal centre
RPA RNase protection assay
SBR Smad binding region
TMCs total mononuclear cells
FCM flow cytometry
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Figure 1.
TGF-β activates an intrinsic apoptotic program in centroblastic BL cells. (a) Western blot
analysis of apoptosis (cleavage of the caspase substrate PARP) and TGF-β signaling
(pSmad2) in a panel of BL cell lines treated with 1ng/ml TGF-β for the times indicated. (b)
Loss of mitochondrial inner membrane potential (ΔΨm) during TGF-β-induced apoptosis of
Ramos cells shown by reduced mean fluorescence of cells labelled with the mitochondrial
stain tetramethlyrhodamine ethyl ester (TMRE). Cells were untreated (dash), labelled with
TMRE alone (solid) or labelled with TMRE and treated with TGF-β (dotted). Cells were
also treated with cyanide-m-chlorophenylhydrazone (CCCP) (thick solid) to cause complete
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membrane depolarisation and serve as a positive control for ΔΨm. Cells were treated for the
times indicated on each histogram and were analysed by flow cytometry.
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Figure 2.
TGF-β-induced apoptosis in BL cells is associated with induction of BIK and
downregulation of BCL-XL. (a) Analysis of transcripts encoding BCL-2 family members by
multiprobe RNAse protection assay (RPA) following TGF-β treatment of BL2 cells. Total
RNA from untreated or TGF-β treated cells was analysed during a 6hr time course. Lanes
corresponding to yeast negative control RNA (Y), undigested probe (P) and 32P-labelled
pBR322 size markers (M) are shown. Sizes of the probe template set are also indicated.
Confirmation of BIK induction (b) and BCL-XL downregulation (c) by Western blot
analysis of RIPA lysates prepared from untreated and TGF-β (1ng/ml) treated BL cell lines.
BIMEL expression was also measured and Smad2/3 levels are shown as a loading control.
TGF-β signaling was analysed by Western blotting for phosphorylation of Smad3 (p-
Smad3). Actin blots are shown as a loading control.
Spender et al. Page 15
Cell Death Differ. Author manuscript; available in PMC 2010 April 20.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 3.
Regulation of BCL-XL and BIK are critical for optimal TGF-β-mediated apoptosis. (a) Flow
cytometry analysis of active caspase-3 positive cells (mean ± s.d., n=3) induced by 24hr
TGF-β treatment in L3055 BL cells and BCL-XL stable transfectants. (b) Western blot
analysis of RIPA extracts from L3055 BL cells and BCL-XL stable transfectants after 48hrs
TGF-β treatment for PARP cleavage, BCL-XL and phospho-Smad2 (p-Smad2). (c) Western
blot analysis of 50μg RIPA extracts from untreated BL cells as indicated. Expression levels
of BCL-XL and BCL-2 in each cell line are shown. A western blot for actin is included as a
loading control. (d) BL2, Ramos and BL40 cells were seeded overnight at 5 × 105/ml and
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then treated for 48 hours with the BCL-XL inhibitor BH3i-2′ (Calbiochem) as indicated.
Apoptosis induction was determined by PI staining and flow cytometry (mean ± s.d., sub-G1
DNA content (n=3)). (e) Ramos cells were left untreated or treated for 48 hours with TGF-β
in the presence or absence of low dose BH3i-2′ (5μM). Apoptosis induction was determined
by PI staining and flow cytometry (mean ± s.d., sub-G1 DNA content (n=3)). (f)
Independent stable cell lines (labelled 1 and 2) expressing non-silencing (NS) and shRNAs
targeted against Bik (Bik#1 and Bik#2) were generated by retroviral infection of Ramos BL
cells. Quantitative real time PCR (qRT-PCR) was used to demonstrate knockdown of BIK in
stable Ramos BL cells. Mean relative amounts of BIK RNA are expressed after
normalisation to 18s rRNA levels. (g) Determination of apoptosis (mean ± s.d., sub-G1
DNA content (n=3)) by PI staining and flow cytometry following TGF-β treatment of cell
lines described in (f).
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Figure 4.
TGF-β directly regulates BIK transcription and induces recruitment of activated Smad
complexes to the BIK promoter. (a) RPAs for BIK and BCL-XL, expression in cells treated
with or without TGF-β and the protein synthesis inhibitors cycloheximide and anisomycin
(C+A) as indicated. Time points -2 and 0 are samples harvested prior to and following
inhibitor treatment respectively. TGF-β was added at 0 hours. (b) RPA for BIK and the
loading control GAPDH following TGF-β treatment of BL cells pretreated for 1 hour with
or without the transcription inhibitor actinomycin D (ActD). Time points -1 and 0 are
samples harvested prior to and following inhibitor treatment respectively. TGF-β was added
at 0 hours. M, P and Y are as described in Figure 2. (c) Real time qRT-PCR carried out on
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RNA isolated from BL cell lines treated with TGF-β in the presence or absence of the
HDAC inhibitor TSA. Shown is the mean ± s.d. amount of RNA normalised to 18s levels
and relative to TGF-β untreated samples. (d) Western blot analysis of 50μg RIPA extracts
from BL cells treated with and without TGF-β in the presence or absence of TSA as
indicated. TGF-β signaling was analysed by Western blotting for phosphorylation of Smads.
A western blot for total Smad2/3 is included as a loading control. (e) Potential Smad binding
regions (SBRs) within the human Bik promoter. Arrows indicate positions of PCR primers
used in ChIP assays shown in (f). (f) ChIP assay for Smad recruitment to the endogenous
Bik promoter in BL cells cultured with and without TGF-β for 1 hour. Input lanes are from
10% of samples used in the IPs performed with control IgG, Smad3 and Smad4 antibodies.
(g) Sequence of ds oligos used in EMSAs shown in (h) containing the potential wildtype and
mutant SBR2 (mSBR2). SBE sequences are shown in bold. (h) EMSA of CA46 nuclear
extracts treated with and without TGF-β for 1 hour as indicated and incubated with wild
type SBR1 and SBR2 and mSBR2. TGF-β inducible and antibody supershifted complexes
are shown (arrowed).
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Figure 5.
Autocrine TGF-β signaling contributes to spontaneous centroblast apoptosis. Flow
cytometry analysis of centroblasts in preparations of explanted normal human tonsil
mononuclear cells (TMCs) showing the percent survival of CD77/CD38 +ve cells (a) and
the percentage of anti-CD77-FITC stained cells remaining after 24 and 48 hours in vitro
culture of TMCs (b) with either exogenous TGF-β or an inhibitor of TGF-β signaling
(SB-431542, 10μM) or solvent control (DMSO). (c) Western blot analysis for PARP
cleavage and actin of extracts from 1×105 purified centroblasts incubated for 36 hours with
TGF-β, SB-431542 or DMSO solvent control. Actin levels are shown as a loading control.
(d) Percent of active caspase-3 negative cells (mean ± s.d., n=3) determined by PhiPhiLux
(G1D2) fluorescent caspase substrate and flow cytometry in purified centroblasts treated
with DMSO (-) or SB-431542 for the indicated times.
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Figure 6.
TGF-β-mediated regulation of BIK and BCL-XL in primary human centroblasts. (a)
Sections of formalin fixed paraffin-embedded human tonsil tissue were stained with
antibodies as indicated and counterstained with haematoxylin. Scale bars represent 200μM.
(b) Western blot analysis of BIK expression in TMCs, TMCs depleted of centroblasts
(CD77 depleted) and isolated centroblasts (purified CD77). A western blot for actin is
included as a loading control. (c) Real time qRT-PCR carried out on RNA isolated from
purified centroblasts treated with zVAD-fmk and -/+ TGF-β for 2-4h (BIK and BIM) or
16-24h (BCL-XL). The mean fold changes in relative RNA expression compared to
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untreated controls are shown. Statistical analysis was carried out using paired t-tests (n=3).
Statistically significant (p) values of <0.005 (**) are indicated.
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Figure 7. Model of centroblastic cell apoptosis pathways
The contribution of TGF-β signaling to regulation of BCL-2 family members is included
alongside known apoptosis pathways functional in germinal centres. The three separate
apoptosis pathways converge to regulate death of human centroblasts. FAS signaling
activates the extrinsic caspase-8/caspase-3 cascade while TGF-β signaling via its receptor
complex represses the prosurvival factor BCL-XL and induces BIK to activate the intrinsic
pathway. Fas and TGF-β signaling contribute to the default apoptotic state of ‘death by
neglect’ while B cell receptor signaling also activates the mitochondrial apoptosis pathway
in cells lacking environmental survival cues. Loss of TGF-β signaling through inhibition of
TGF-β receptor signaling by SB-431542 would reduce the amount of caspase-3 activation
and raise the threshold for apoptosis induction. The model highlights the requirement for
maintenance of cFLIP and BCL-XL levels for cells to survive during germinal centre
reactions.
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